Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

SpO2 Validation of Noninvasive Red Diamond Disposable Pulse Oximeter Sensor

6 agosto 2019 aggiornato da: Masimo Corporation
In this study, the level of oxygen within the blood will be reduced in a controlled manner by reducing the concentration of oxygen the study volunteer breathes. The accuracy of a noninvasive pulse oximeter sensor will be assessed by comparison to the oxygen saturation measurements from a laboratory blood gas analyzer.

Panoramica dello studio

Stato

Completato

Condizioni

Tipo di studio

Interventistico

Iscrizione (Effettivo)

35

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • California
      • Irvine, California, Stati Uniti, 92618
        • Masimo Corporation

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 50 anni (Adulto)

Accetta volontari sani

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria (Eligible Subjects)

  • Competent non-smoking (smokers including e-cigarette users) adults between the ages of 18 and 50 years of age.
  • We may also be interested in specifically recruiting smokers for some portions of this study as well as non-smokers for other portions of this study.
  • Must weigh a minimum of 110 lbs and no more than 250 lbs unless subject is over 6 feet tall.
  • BMI less than or equal to 35
  • Must have a hemoglobin value greater than or equal to 11 g/dL.
  • Baseline heart rate 45 bpm to 85 bpm.
  • CO value less than or equal to 2.0% FCOHb (unless we are specifically interested in recruiting smokers)
  • Physical status of ASA I or II (American Society of Anesthesiology Class 1; Healthy subjects without any systemic disease at all. American Society of Anesthesiology Class II; subjects with mild systemic disease)
  • Blood Pressure (Systolic BP less than or equal to 140 mmHg and Diastolic BP less than or equal to 90 mmHg).
  • Able to read and communicate in English
  • Has signed written informed consent
  • Female, non-pregnant.
  • Female subjects will be provided with a pregnancy test free of charge.

Exclusion Criteria (Ineligible subjects)

  • Subjects who do not understand the study and the risks involved.
  • Subjects with open wounds, lacerations, inflamed tattoos or piercings, visible healing wounds.
  • Subjects with frequent or severe headaches and/or migraine headaches.
  • Subject has known drug or alcohol abuse. Subjects who uses recreational drugs.
  • Subject has experienced a head injury with loss of consciousness within the last year.
  • Any chronic bleeding disorders (i.e. hemophilia)
  • Any history of a stroke, myocardial infarction, seizures or heart attack.
  • Any cancer or history of cancer (not including skin cancer).
  • Chronic neurological diseases (i.e. multiple sclerosis, Huntington's Disease).
  • Any cardiac dysrhythmias (i.e. atrial fibrillation)(without physicians clearance)
  • Subject has known neurological and/or psychiatric disorder (i.e. schizophrenia, bipolar disorder) that interferes with the subjects' level of consciousness.
  • Known or concurrent chronic usage of psychoactive or anticonvulsive drugs. Subjects with psychiatric conditions or are on psychiatric medications (i.e. tricyclic antidepressants, MAO inhibitors, Lithium, neuroleptics, anxiolytics or antipsychotics, except SSRIs).
  • Subject has any medical condition which in the judgment of the investigator and/or medical staff, renders them ineligible for participation in this study, such as Reynauds Syndrome.
  • Subject has Wolff-Parkinson-White Syndrome or Stokes-Adams Syndrome
  • Inability to tolerate sitting still or maintain minimal movement for up to 90 minutes.
  • For studies involving finger sensors: subjects with polished, gel or acrylic nails, skin abnormalities affecting the fingers or arms (such as psoriasis, eczema, angioma, scar tissue, burn, fungal infection), distinct finger edema, substantial skin breakdown damaged and/or finger nail deformities (specific finger will not be used, unless we are specifically testing sensors in use with nail polish, gel, and /or acrylic nails).
  • Subjects who have/are currently taking anticoagulant medication.
  • Subjects who have had caffeine consumption the day of the study.
  • Subjects who have taken pain medication within 24 hours of start of study. Unless minimal preventative dose recommended for adults (discretion of physician).
  • Subjects having either signs or history of peripheral ischemia.
  • Subjects who have had invasive surgery within the past year- including but not limited to major dental surgery, gallbladder, heart, appendix, major fracture repairs (involving plates/ screws), jaw surgery, Urinary tract surgery, plastic surgery, major ENT surgery, joint replacement or gynecological surgeries, heart surgery or thoracic surgery.
  • Subjects who have had minor surgery or conditions in the past two months including but not limited to minor foot surgery (bunion), arthroscopic procedure, blood donation, plasma donation, skin biopsy/ procedures, root canal, fractures, eye surgery, and other minor procedures.
  • Subjects that have been on antibiotics had congestion, head colds, flu, ear infection, chest congestion will have a 2 week waiting period from the time of finishing medications and must have no more symptoms.
  • Subjects with claustrophobia, or anxiety.
  • Subjects who have been in severe car accidents or a similar type of accidents will have a 12 month waiting period, from the time of the accident; unless upon further medical history questions the physician determines it does not place the subject in any additional harm, increase their risk, or compromise the subjects' safety.
  • Subjects who have had a concussion will have a 12 month waiting period, from the time of the concussion.
  • Subjects with chronic unresolved asthma, lung disease or respiratory disease.
  • Subjects with allergies to lidocaine, latex, adhesives, or plastic.
  • Subjects with heart conditions, Diabetes or hypertension.
  • Subjects who have given vaginal delivery will have a 6 month waiting period. Subjects who had a pregnancy terminated, a miscarriage or had a C-section will have a 12 month waiting period.
  • Subjects who intend on participating in any heavy lifting, repetitive movement of their wrist (including riding a motorcycle) or exercise (working out, riding a bike, riding a skate board etc.), or any activity that will put additional stress on the wrist within 24 hours following a study involving an arterial blood draw and/or arterial line placement.
  • Discretion of investigator/study staff

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Test Subject
All subjects are enrolled into the test group and all subjects receive the noninvasive Red Diamond Disposable Pulse Oximeter Sensor
Noninvasive Pulse Oximeter Sensor

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Accuracy of Red Diamond Disposable Pulse Oximeter Sensor by Arms Calculation
Lasso di tempo: 1-5 hours per subject
Accuracy will be determined by comparing the noninvasive blood oxygen saturation measurement of the pulse oximeter to that obtained from a blood sample and calculating the Accuracy root mean square (ARMS) error value. In order to obtain the Arms value, the blood oxygen saturation measurement form a laboratory pulse Co-Oximeter is subtracted from the pulse oximeter oxygen saturation measurement for a number of samples, the average of this difference is computed as the bias. The standard deviation of the differences is computed as the precision. The square root of the sum of the squares of bias and precision is computed as the ARMS Error value.
1-5 hours per subject

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

7 marzo 2017

Completamento primario (Effettivo)

11 maggio 2017

Completamento dello studio (Effettivo)

11 maggio 2017

Date di iscrizione allo studio

Primo inviato

14 aprile 2017

Primo inviato che soddisfa i criteri di controllo qualità

20 aprile 2017

Primo Inserito (Effettivo)

24 aprile 2017

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

22 agosto 2019

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 agosto 2019

Ultimo verificato

1 agosto 2019

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • TP18604A_195

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi